NO954681L - Chemical connections - Google Patents

Chemical connections

Info

Publication number
NO954681L
NO954681L NO954681A NO954681A NO954681L NO 954681 L NO954681 L NO 954681L NO 954681 A NO954681 A NO 954681A NO 954681 A NO954681 A NO 954681A NO 954681 L NO954681 L NO 954681L
Authority
NO
Norway
Prior art keywords
zero
group
rsome
integers
electron
Prior art date
Application number
NO954681A
Other languages
Norwegian (no)
Other versions
NO954681D0 (en
Inventor
Peter Clive Cherry
John Derek Cocker
Andrew David Searle
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO954681L publication Critical patent/NO954681L/en
Publication of NO954681D0 publication Critical patent/NO954681D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Oppfinnelsen vedrører "substituerte karbazol-derivater, fremgangsmåter for deres fremstilling, farmasøytiske blandinger som inneholder slike og deres medisinske anvendelse for reduksjon av østrogen- og/eller androgen-nivåer.Spesielle forbindelser ifølge oppfinnelsen er forbindelser med formel (I). hvor Rx og Ruavhengig av hverandre, utgjør et hydrogenatom eller en C-alkylgruppe; hver av Rsom kan være like eller forskjellige, utgjør en elektron-tiltrekkende gruppe; hver av Rsom kan være like eller forskjellige, utgjør en elektron-tiltrekkende gruppe; Rer en gruppe med formel. er et halogenatom, en C-alkylgruppe eller en C^-alkoksy-gruppe;. i m er null eller et av heltallene 1 til 4;. n er null eller et av heltallene 1 til 3; og p er null, 1 eller 2. og farmasøytisk akseptable salter og solvater derav.The invention relates to "substituted carbazole derivatives, processes for their preparation, pharmaceutical compositions containing them and their medicinal use for reducing estrogen and / or androgen levels. Particular compounds of the invention are compounds of formula (I). Wherein R each other, form a hydrogen atom or a C-alkyl group; each of Rsome may be the same or different, constitutes an electron-withdrawing group; each of Rsome may be the same or different, constituting an electron-attracting group; is a halogen atom, a C 1-4 alkyl group or a C 1-4 alkoxy group; i m is zero or one of the integers 1 to 4; n is zero or one of the integers 1 to 3; and p is zero, 1 or 2. and pharmaceutically acceptable salts and solvates thereof.

NO954681A 1993-05-21 1995-11-20 Chemical connections NO954681D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939310635A GB9310635D0 (en) 1993-05-21 1993-05-21 Chemical compounds
PCT/EP1994/001613 WO1994027989A1 (en) 1993-05-21 1994-05-19 Carbazole derivatives with 17,20-lyase-inhibiting activity

Publications (2)

Publication Number Publication Date
NO954681L true NO954681L (en) 1995-11-20
NO954681D0 NO954681D0 (en) 1995-11-20

Family

ID=10736007

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954681A NO954681D0 (en) 1993-05-21 1995-11-20 Chemical connections

Country Status (19)

Country Link
EP (1) EP0699196A1 (en)
JP (1) JPH08510455A (en)
CN (1) CN1126473A (en)
AU (1) AU6928794A (en)
BG (1) BG100154A (en)
CA (1) CA2162921A1 (en)
CZ (1) CZ305195A3 (en)
FI (1) FI955587A (en)
GB (1) GB9310635D0 (en)
HU (1) HUT73790A (en)
IL (1) IL109703A0 (en)
NO (1) NO954681D0 (en)
OA (1) OA10195A (en)
PE (1) PE31195A1 (en)
PL (1) PL311702A1 (en)
SK (1) SK142495A3 (en)
TW (1) TW279866B (en)
WO (1) WO1994027989A1 (en)
ZA (1) ZA943494B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009157A1 (en) * 1993-09-30 1995-04-06 Yamanouchi Pharmaceutical Co., Ltd. Azole derivative and pharmaceutical composition thereof
AU3846395A (en) * 1994-11-07 1996-05-31 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
AU702406B2 (en) * 1995-03-01 1999-02-18 Yamanouchi Pharmaceutical Co., Ltd. Imidazole derivatives and medicinal composition thereof
AU6229698A (en) * 1997-02-21 1998-09-09 Takeda Chemical Industries Ltd. Fused ring compounds, process for producing the same and use thereof
KR100725442B1 (en) 2000-11-17 2007-06-07 다케다 야쿠힌 고교 가부시키가이샤 Novel imidazole derivatives, production method thereof and use thereof
AU2002214320A1 (en) 2000-11-20 2002-05-27 Takeda Chemical Industries Ltd. Imidazole derivatives, process for their preparation and their use
AU2002221080A1 (en) 2000-12-08 2002-06-18 Masami Kusaka Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
CN101203491A (en) 2005-06-24 2008-06-18 伊莱利利公司 Tetrahydrocarbazole derivatives used as androgen receptor modifier
GB0525323D0 (en) * 2005-12-13 2006-01-18 Sterix Ltd Compound
US8093279B2 (en) 2005-12-13 2012-01-10 Gillian Reed, legal representative Compound
CN100586932C (en) * 2007-01-26 2010-02-03 中国医学科学院医药生物技术研究所 Antitumor compound and its preparation process
MY155570A (en) 2009-06-26 2015-10-30 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
EP2531029B1 (en) * 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
WO2011143469A1 (en) 2010-05-12 2011-11-17 Radius Health,Inc Therapeutic regimens
WO2012018948A2 (en) 2010-08-04 2012-02-09 Pellficure Pharmaceuticals, Inc. Novel treatment of prostate carcinoma
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
WO2012047617A1 (en) 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
EP2702052B1 (en) 2011-04-28 2017-10-18 Novartis AG 17alpha-hydroxylase/c17,20-lyase inhibitors
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US20160022606A1 (en) 2013-03-14 2016-01-28 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
EP3834824A1 (en) 2014-03-28 2021-06-16 Duke University Method of treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
US10093620B2 (en) 2014-09-12 2018-10-09 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
EP3528799A1 (en) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
JP7481115B2 (en) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Polymorphic forms of RAD1901-2HCL

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229934B2 (en) * 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds

Also Published As

Publication number Publication date
EP0699196A1 (en) 1996-03-06
CN1126473A (en) 1996-07-10
HUT73790A (en) 1996-09-30
PE31195A1 (en) 1995-10-18
CZ305195A3 (en) 1996-06-12
FI955587A0 (en) 1995-11-20
IL109703A0 (en) 1994-08-26
HU9503321D0 (en) 1996-01-29
BG100154A (en) 1996-07-31
WO1994027989A1 (en) 1994-12-08
CA2162921A1 (en) 1994-12-08
AU6928794A (en) 1994-12-20
TW279866B (en) 1996-07-01
GB9310635D0 (en) 1993-07-07
NO954681D0 (en) 1995-11-20
JPH08510455A (en) 1996-11-05
OA10195A (en) 1996-12-18
SK142495A3 (en) 1996-06-05
PL311702A1 (en) 1996-03-04
ZA943494B (en) 1995-01-23
FI955587A (en) 1995-11-20

Similar Documents

Publication Publication Date Title
NO954681L (en) Chemical connections
DK0794949T3 (en) New 3,5-dioxo (2H, 4H) -1,2,4-triazine derivatives, their preparation and their use as pharmaceuticals
HUP0401009A2 (en) 1-aryl-or 1-alkylsulfonylbenzole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions containing them
MY119150A (en) Azetidine derivatives, their preparation and medicaments containing them
ES8203883A1 (en) Imidazole derivatives, their preparation and compositions containing them.
NO986055D0 (en) New heterocyclic compounds, their preparation, pharmaceutical preparations
HUP0402225A2 (en) Macrolide-compounds, process for their preparation and pharmaceutical compositions containing them
NO20022558L (en) 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor
HUT67788A (en) 2,4-dioxo-thiazolidine derivatives, their preparation and pharmaceutical compositions containing them
HK1052697A1 (en) Novel benzothiadiazine derivatives, preparation method and pharmaceutical compositions containing same.
HU9204121D0 (en) Thiazolidine derivatives containing quinone group, method for producing them and medical preparatives containing these compounds
IE872658L (en) Tetrahydroquinoline derivatives, a process for their preparation, their use and pharmaceutical formulations containing them
ES2005582A6 (en) 1-(hydroxystyrl)-5H-2,3-benzodiazepine derivatives, and pharmaceutical compositions containing the same
ES8605760A1 (en) (Omega-(diethylamino)-alkoxy)-alpha-(ethyl)-benzhydrol derivatives, their acid addition salts and quaternary salts, process for their preparation and medicines containing these compounds.
NO882334L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ALKANSULPHONANILIDE DERIVATIVES.
AU649099B2 (en) Use of 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine derivatives as free radical scavengers
DK0408044T3 (en) Anti-inflammatory and / or antiallergic preparation comprising glutathione derivatives
DK661088A (en) N- (23-VINBLASTINOYL) DERIVATIVES OF 1-AMINOMETHYLPHOSPHONIC ACID, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL AGENTS CONTAINING THEM
ES2001893A6 (en) Methylendioxyphenathrene and stilben derivatives, process for the preparation thereof, pharmaceutical compositions using these, and therapeutic applications
HUP0202647A2 (en) Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
HUP0202438A2 (en) Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation
WO1987007609A1 (en) 1,1,2-triaryl-1-butene derivatives
IT1150955B (en) 3H-NAFT (1.2-D) -IMIDAZOLIC DERIVATIVES THE PROCEDURE FOR THEIR PREPARATION, THEIR USE AS ANTI-INFLAMMATORY AGENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NO20035026D0 (en) Dihydroimidazo [5,1-A] - <beta> -carboline derivatives, process for their preparation and use thereof as a drug
NO20010801L (en) New 6-amino- or 6-hydroazino-sulfonyl-3-quinolynylphosphonic acid compound, process of their preparation and pharmaceutical compositions containing them